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INTRODUCTION
Acute mountain sickness (AMS) is a hypoxia- induced symptom
at high altitude and can progress to high altitude pulmonary edema
(HAPE) or high altitude cerebral edema (HACE) (1). HAPE is a life -
threatening non-cardiogenic pulmonary edema that occurs in many
mountaineers at high altitudes with the high mortality rate (2) and
remains to be the major cause of death in the absence of adequate
emergency treatment. In general, HAPE is caused by hypoxia-
induced pulmonary artery pressure that results in interstitial and
alveolar pulmonary edema, as well as impaired oxygenation (3).
According to the Lake Louise Consensus, in the context of a recent
ascent, patients with HAPE will have some combination of the fol-
lowing symptoms and signs, including dyspnea at rest, cough,
weakness or decreased exercise performance, chest tightness,
central cyanosis, tachypnea, and tachycardia. In practice, the diagno-
sis is usually clinically apparent. The treatment of HAPE includes
descent, rest, and administration of oxygen or Dexamethasone.
However, treatments for this disease vary considerably because
the underlying pathophysiologic mechanisms remain unclear. The
most possible and crucial pathological mechanism for HAPE is
hypoxia- induced capillary permeability (4). Recently, much work
has focused on the role of vascular endothelial growth factor
(VEGF) that is mainly expressed in lung and brain choroid plexus
and demonstrated it is a potent vascular permeability factor under
hypoxia(5). However, it remains to be determined whether circu-
lating VEGF in blood is a key factor that contributes to the patho-
genesis of HAPE since VEGF levels are not consistently increased in
AMS patients (6, 7). Soluble fms- like tyrosine kinase-1 (sFlt -1) is a
splice variant of VEGF receptor which is produced by a variety of
tissues (8) and is able to bind VEGF to reduce its free circulating
levels and bioactivity (9). Interestingly, Flt -1 levels are also dra-
matically stimulated in most of cases of hypoxia (10). It has been
reported that in addition to bind VEGF, Flt -1 also antagonizes and
reduces bioactivities of other pro-vascular permeability factors
such as PIGF (11), semaphoring 3A (Sema3A)(12) and Galectin-1
(Gal -1)(13). In HAPE, however, the role of sFlt -1 remains un-
known. Currently, two studies have showed sFlt -1 plays the insig-
nificant role in AMS (7, 14).
In this study, we have studied and demonstrated the potential
roles of plasma VEGF and sFlt -1 in HAPE development by compar-
ing plasma levels of VEGF and sFlt -1 among cohorts of amateur
mountaineers with or without HAPE in Qinghai province, China.
METHODS
Research subjects
Selected healthy subjects were selected by using following pre-
determined criteria : at age range 20-45ys, no significant medical
conditions including diabetes, hypertension, cardiovascular dis-
ease and chronic pulmonary disease, no recent exposure to high
altitude, no history of HAPE or HACE, and not involved in profes-
sional climbing/mountaineering training. The human research
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ethical committee from Qinghai Provincial Hospital approved the
study protocol and all subjects signed written informed consent
form.
Research subjects participated in three mountaineering activi-
ties in Golmud (2800 m) and Yuzhu Peak (5050 m) between May
2013 and Oct 2013.The Lake Louise Score evaluation for acute
mountain sickness (AMS) and clinical assessments were per-
formed on day 0 (2800 m), day 3(4500 m), and day 5 (5050 m). The
Lake Louis Consensus definition of HAPE was defined as in the
setting of recentaltitude gain with the presence of the at least two of
symptoms : dyspnoea at rest, weakness or decreased exercise per-
formance, cough, chest tightness or congestion, and the presence
of at least two of signs : tachypnoea, tachycardia, crackles, or
wheezing in at least one lung f ield, and central cyanosis (15).
Evaluation of HAPE severity
According to Lake Louise Criteria, the diagnosis of HAPE was
made by at least two of the following symptoms : shortness of
breath at rest, cough, weakness and decreased exercise perform-
ance, chest tightness or congestion ; AND at least two of the fol-
lowing signs on physical exam : fast heart rate, fast breathing,
crackles or wheezing heard in the lungs, or low oxygen meas-
ured by a pulse oximeter. Chest X-ray in HAPE patient confirms
fluid in the lungs. After hospitalization, patients were treated
immediatedly with bed rest, oxygen, Dexamethasone. Demo-
graphic and clinical features immediately recorded included age,
sex, self -reported previous history of HAPE, rate of ascent,
altitude at onset of symptoms, physical examination findings, and
vital signs including pulse oximetry were recorded. HAPE patients
were classified into three groups : mild, moderate, and severe (16).
Among 20 subjects who were born and resided at low altitude, 10
did not have any symptoms during all activities, and another 10
developed HAPE. All HAPE patients were transferred to hospital
within 2-3 hours. The diagnosis of HAPE was confirmed and pa-
tients were recovered with disappearance of symptoms and signs
during 3 days of treatments with bed rest and supplemental oxygen,
and chest radiographic infiltrates consistent with pulmonary
edema.
Blood samples
Venous blood was drawn from the patients with HAPE at the
time of admission before treatment and discharge from the hospi-
tal. Meanwhile, the blood samples were also drowned from non-
HAPE subjects right after they arrived at the low (2800 m) and the
high altitude camp (5050 m) ; all the blood samples were trans-
ported with ice, centrifuged immediately after receiving at 3000
rpm for 15 min, and stored at -80 until assays.
ELISA assay
Plasma levels of sFlt -1 and VEGF were determined in duplicate
using Quantikine ELISA kits for human VEGF and Flt -1 (R&D
Systems, Minneapolis, USA) according to the manufacture guid-
ance. For plasma VEGF or sFlt -1 quantification, 100 μl of standards
and undiluted plasma were added and incubated for 1 h at room
temperature in the 96-well plate coated with monoclonal VEGF or
sFlt -1 capture antibody.
Statistics
Paired Student’s t - test was used to analyze the data obtained
from HAPE patients before and after treatment. Whitney U test was
used to analyze data obtained from HAPE patients and non-HAPE
subjects. Correlations between VEGF and/or sFlt -1 and HAPE se-
verity were also determined. Data are expressed as meanS.E.
Significance was set at p0.05 for all statistical analyses.
RESULTS
The anthropometric plasma levels of VEGF and sFlt -1 in all
subjects were determined and presented in Table 1. After treat-
ment, monitoring indexes, including HR, SpO2, and body tempera-
ture were significantly improved comparing to pre-treatment.
Plasma levels of both VEGF and sFlt -1 in HAPE patients were
dramatically increased as compared to non-HAPE at the same alti-
tude (5050 m) (VEGF : 1117.7446.98 pg/ml vs. 432.86103.38
pg/ml, p0.01 ; sFlt -1 : 389.7376.89 pg/ml vs. 15.425.39 pg/
ml, p0.01) (Figure 1, A, B). Interestingly, there was a 25- fold
increase in sFlt -1 levels as compared to a 2.6- fold increase in VEGF
levels. As expected, in HAPE patients, elevated plasma levels of
VEGF and sFlt -1 in patients were significantly reduced after pa-
tients were recovered in the hospital (VEGF : 1117.7447.01 vs
25224.56, p0.01 ; sFlt -1 : 389.7324.33 vs 22.346.96, p0.01)
(Figure 2, A, B). Again, sFlt -1 levels were decreased much more
than VEGF levels after recovery (4.4 fold vs. 17.4 fold). Clearly,
sFlt -1 changes were much bigger during hypoxia and treatments.
Additionally, ratios of sFlt -1 and VEGF were compared between
the non-HAPE group and the before treatment group in HAPE
patients (0.080.03 vs 0.350.02, p0.01) or the after treatment
group (0.090.03 vs. 0.250.04, p0.05). We found the sFlt -1 al-
teration without considering VEGF effects might be more mean-
ingful for patient assessments (Figure 3, A, B).
DISCUSSION
It was well accepted that VEGF induced pulmonary hyperten-
sion and vascular permeability after its binding to endothelial cells
(17). VEGF is a powerful mediator of capillary permeability by
disrupting basement membrane ligands, thus increasing capillary
permeability and leading to plasma leak from capillaries (18).
Previous studies have evaluated the circulating VEGF in the patho-
genesis of AMS, however, the function of VEGF in HAPE remain
inconclusive ; As an antagonist, sFlt -1 was able to sequester circu-
lating VEGF to inhibit its binding to the endothelium-bound recep-
tors to stimulate VEGF-induced vascular permeability . However, it
remained unclear why both factors were sometimes increased to-
gether in hypoxia and whether/how these two factors could be
Table1 : The anthropometric data analysis of subjects
Characteristic
Non-HAPE
Conrols
(n=10)
HAPE Patients
(n=10)
Before
treatment
After
treatment
Age, yrs 29.410.04 30.085.00
Height, cm 175.223.17 172.004.43
Weight, Kg 72.007.15 68.707.42
BMI, Kg/m2 22.853.38 22.633.22
SBP, mmHg 119.9218.32 118.917.54 120.864.62
DBP, mmHg 83.2811.56 77.103.78 72.741.82
HR, min -1 78.2510.56 113.0618.90 82.5312.83
SpO2, % 91.051.41 65.983.62 89.721.94
Temperature
(Celsius
degree)
36.770.09 36.530.10 37.30.08
 Significant between before treatment and after treatment group.
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used to assess the hypoxia condition in HAPE. Importantly, several
studies suggested that these two factors were not consistently in-
duced in AMS. Most studies showed that circulating VEGF was
significantly increased in AMS or HAPE patients at high altitude (7,
19). However, at least in one study, plasma VEGF level was little
changed between AMS+ and AMS- subjects at high altitude (14). In
sFlt -1 studies, Schommer showed sFlt -1 was increased but not sig-
nificantly between AMS+ and AMS-(14). Another study even dem-
onstrated that AMS subjects had lower sFlt -1 levels at both low and
high altitude compared to control subjects (7). In addition, the
level of VEGF in this study was much higher than those in previous
research. We believed these discrepancies might be attributable to
different sample collecting time. Among these studies and our
study, we clearly showed that plasma levels of both VEGF and
sFlt -1 were significantly increased in HAPE patients as compared
to non-HAPE individuals and recovered patients. We found that
sFlt -1 was much more sensitive to hypoxia than VEGF, suggesting
other pro-vascular permeability factors that also bound to sFlt -1
might be involved as well. Our data suggested sFlt -1 could be a
better biomarker to assess HAPE. In blood samples collected from
people around 5 days after entering high altitude, we observed
marked increases in plasma levels of both VEGF and sFlt -1 in
HAPE patients. In contrast, a previous study showed one day after
reaching high altitude, VEGF was elevated but not significantly and
sFlt -1 was even decreased. These data suggested that these two
factors were not quick responding biomarkers for hypoxia and the
blood collection time was crucial. In addition, in our study, after
exposure to hypoxia, sFlt -1 levels were increased much more than
VEGF in HAPE patients, suggesting that VEGF might not be the
only factor that was involved in HAPE pathogenesis and other
factors that bound with sFlt -1 and induced vascular permeability
might also be involved in HAPE development (12, 13). To prove this
concept, we compared the sFlt -1/VEGF ratios among groups to
eliminate the VEGF effect and clearly demonstrated that the ratio
was dramatically altered in patients before and after treatments.
Plasma levels of both VEGF and sFlt -1 were significantly in-
creased during HAPE development and markedly reduced after
treatments. In our case, sFlt -1 might contribute more to HAPE
pathogenesis since it was much more sensitive to hypoxia and
A
B
Figure 1. Plasma levels of VEGF and sFlt -1 in HAPE (n=10) and
control (n=10) subjects at Yuzhu peak camp (5050 m). A, the mean
plasma level of VEGF in HAPE patients was significantly increased as
compared with control subjects. B, the plasma level of sFlt -1 was signifi-
cantly increased in subjects who developed HAPE as compared to control
individuals. **p0.01.
A
B
Figure 2. Plasma levels of VEGF and sFlt -1 in HAPE patients(n=10)
before and after treatments. A. Plasma levels of VEGF were significantly
higher in the before treatment group and reduced after treatments. B.
Similarly, plasma levels of sFlt -1 level were increased at the onset of
HAPE and decreased after treatments. **p0.01
66 S. Zhang, et al. Plasma VEGF and sFlt-1 are associated with HAPE
treatments as compared to VEGF response. Our data suggested
sFlt -1 might be another important factor that was involved in HAPE
pathogenesis and the sFlt -1/VEGF ratio could be used as a sensi-
tive diagnostic marker for HAPE diagnosis and treatments. Al-
though we found sFlt -1/VEGF ratio significantly decreased with
the improvement of HAPE condition, other factors, such as the
differences of hospital length of stay, treatments, and patients’ per-
sonal constitution, might affects the results as well. In addition,
despite these intriguing findings, the weakness of this study is lim-
ited sample size, future studies of larger cohorts are necessary to
assess the diagnostic performance and significance of our observa-
tions linking circulating VEGF and sFlt -1 levels to HAPE condition.
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